241 related articles for article (PubMed ID: 33806916)
1. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
[TBL] [Abstract][Full Text] [Related]
2. Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species.
Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
Xenobiotica; 2024 Apr; ():1-13. PubMed ID: 38647387
[No Abstract] [Full Text] [Related]
3. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
4. Polatuzumab Vedotin: First Global Approval.
Deeks ED
Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604
[TBL] [Abstract][Full Text] [Related]
5. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Samineni D; Ding H; Ma F; Shi R; Lu D; Miles D; Mao J; Li C; Jin J; Wright M; Girish S; Chen Y
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S120-S131. PubMed ID: 33205435
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
8. Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Dere RC; Beardsley RL; Lu D; Lu T; Ku GH; Man G; Nguyen V; Kaur S
Front Immunol; 2023; 14():1119510. PubMed ID: 37063860
[TBL] [Abstract][Full Text] [Related]
9. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.
Assi R; Masri N; Dalle IA; El-Cheikh J; Ghanem H; Bazarbachi A
Clin Hematol Int; 2021 Mar; 3(1):21-26. PubMed ID: 34595463
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; ():. PubMed ID: 38622879
[TBL] [Abstract][Full Text] [Related]
12. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
15. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract][Full Text] [Related]
17. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
18. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
